Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
12 août 2024 07h30 HE
|
Abeona Therapeutics Inc.
Significant progress addressing CMC items noted in CRL BLA resubmission remains on track for 2H 2024 CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 août 2024 07h30 HE
|
Abeona Therapeutics Inc.
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
11 juil. 2024 07h30 HE
|
Abeona Therapeutics Inc.
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and...
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
08 juil. 2024 07h30 HE
|
Abeona Therapeutics Inc.
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 juin 2024 07h30 HE
|
Abeona Therapeutics Inc.
CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
28 mai 2024 07h30 HE
|
Abeona Therapeutics Inc.
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies...
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
15 mai 2024 07h30 HE
|
Abeona Therapeutics Inc.
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 mai 2024 07h30 HE
|
Abeona Therapeutics Inc.
CLEVELAND, May 07, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
03 mai 2024 07h30 HE
|
Abeona Therapeutics Inc.
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its...
Abeona Therapeutics Provides Regulatory Update on Pz-cel
22 avr. 2024 16h05 HE
|
Abeona Therapeutics Inc.
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new...